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A B S T R A C T
In pharmaceuticals manufacturing, the conversion of conventional batch crystallisations to continuous
mode has the potential for intensified, compact operation andmore consistent production via quality-by-
design. A pragmatic conversion approach is to utilise existing stirred tank batch crystallisers as
continuous mixed-suspension mixed-product removal (MSMPR) stages. In this study, a rigorous and
general mathematical model is developed for a pharmaceutical crystallisation process under continuous
MSMPR operation. In the proposed changeover from batch to continuous operation, concentration
control (C-control), which has been well accepted in batch crystallisation operation, is further extended
to facilitate the convenient design of the steady-state operating point of a continuous MSMPR
crystalliser; an objective is to ensure that the start-up procedures and on-line control conditions fall
within the design-space of the original batch operation. Both single-stage and cascaded two-stage
MSMPR crystallisers were investigated and compared to the conventional batch operation. It was
observed that despite the production of a smaller number-based mean crystal size, the proposed
continuous MSMPR operation achieved higher production capacity with shorter mean residence time
and comparable product yield to the batch operation. Lastly, the robustness of C-control strategy against
uncertainties in crystallisation kinetics was also demonstrated for the proposed continuous MSMPR
operation.
ã 2015 Elsevier B.V. All rights reserved.
1. Introduction
Crystallisation is an important unit operation for separation and
purification in the process industries, such as in the pharmaceut-
icals, food, and fine chemicals sectors, in which a solid crystalline
product with desired purity, size, and shape may be obtained from
an impure feed solution. Conventionally, crystallisation processes
are operated in batch mode to allow flexibility to respond to
varying customised design requirements and changing market
demands; however, this approach can also lead to increased
manufacturing costs and batch-to-batch variations in product
quality. The advent of patent expiration of many bulk drugs [1] has
generated an increasing need to become more competitive
through advanced manufacturing technologies [2]. Hence the
development of continuous manufacturing and crystallisation
techniques has received increasing interest and research effort
from academic and industrial sectors in the past decade, due to the
potential advantages of reduced costs, shorter development time,
more robust scale-up and improved control performance [1,3,4].
To date, there are threemain types of continuous crystalliser that
have been widely investigated for this purpose, viz., the mixed-
suspension mixed-product removal (MSMPR) reactor [5], the plug
flow reactor (PFR) [6], and the continuous oscillatory baffled
crystalliser (COBC) [7]. Currently, the most dominant crystalliser
type used in the pharmaceutical industries for batch operations is
based on a stirred tank design. In addition, quantitative quality risk
assessments of new continuous crystalliser platforms are not yet
fully understood and there is limited information regarding their
implementation on commercial scale plant installations [1]. The
approval of new process platforms will be strictly regulated and
therefore it may be practical to gradually convert existing
batch operations to continuous mode by operating the stirred tank
in an MSMPR mode. Such a changeover could be easier and more
cost-effective than replacing existing capital equipment with
completely new continuous crystalliser designs [8].
Towards this end, recent experimental and engineering efforts
have been devoted to the implementation of continuous MSMPR
crystallisers for pharmaceutical and fine chemical compounds. For
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example, Sen et al. [9] optimised the start-up of a continuous
pharmaceutical manufacturing process, wherein the cooling
schedule of a continuous MSMPR crystalliser was taken into
account. Griffin et al. [10] studied the integration and application of
product classification and a recycle stream to a continuousMSMPR
crystalliser, in order to obtain a small mean crystal size with a
narrow size distribution. Similar studies of a continuous MSMPR
crystalliser with a recycle stream for cooling and combined
cooling–antisolvent crystallisations were reported by Wong
et al. [11]. Furthermore, a series of investigations on cascaded
multi-stage, continuous MSMPR crystallisers were conducted
for cooling, antisolvent, and reactive crystallisations at the
Novartis-MIT Center [12–14].
For many years, researchers and designers have made
modelling assumptions and applied equations for MSMPR
crystallisers, whichwere originally developed for sparingly soluble
inorganic solute systems, by considering negligible solute and solid
volumes [5], and have applied them to more highly soluble
pharmaceutical compounds. This can lead to inaccurate calculation
of the solute concentration, slurry volume, and mean residence
time in a continuous operation. In some models the solute
concentration and crystal size distribution are expressed per unit
mass of solvent, but the nucleation kinetics are most oftenwritten
per volume of solution; hence unit conversions of the kinetic
equations are often necessary to incorporate them into the mass
balance and population balance equations, duringwhich the solute
and solid volumes are often neglected [15]. Therefore, an aim of the
current work is to develop a general mathematical modelling
framework for an MSMPR crystalliser intended for pharmaceutical
and fine chemical industries, by more rigorously taking into
account solute and solid volumes, upon which the changing
operations from batch to continuous crystallisation mode by
MSMPR could be studied, optimised, and controlled.
The concentrationcontrol (C-control) approach iswell known for
itsrobustnessagainstuncertaintiesincrystallisationkinetics,since it
was originally designed for batch crystallisation control. The general
idea of C-control is to determine an optimal solute concentration or
supersaturation trajectory in the phase diagram, for example,
concentration vs. temperature or concentration vs. antisolvent
mass fraction; a feedback control system is then designed to
maintain the optimal relationship between these state variables
[16–19]. Detailed uncertainty and disturbance analyses carried out
both experimentally and in simulations have shown that the
approach ensures the consistent production of large crystals by
suppressing excessive nucleation and the formation of undesired
polymorphs [17,18,20–22]. In light of this, it would be useful to
extend and exploit the robustness of C-control, with minimal
additional effort, for the changeover from batch to continuous
operations. One of the possibleways is to start up the crystallisation
process following the optimal solute concentration trajectory
[23–25], as in batch operation, and then switch to continuous
operation after the solute concentration reaches a certain point on
the optimal concentration trajectory. Control loops are then
implemented to regulate the crystalliser temperature and the
addition of fresh solution and/or antisolvent in order to maintain
the continuous operation at this specific point. In such away, all the
conversion procedures, from batch to continuous operation, are
within the design-space of the original batch process, which should
have been approved already by regulatory agencies.
To sum up accordingly, the present study considers a rigorous
and general modelling framework for a crystallisation process
using a stirred tank design which is seldom discussed in the open
literature. Additionally, to the authors’ knowledge, this is the first
time that a pragmatic solution is investigated for converting
existing batch crystallisation operation and its control technique to
continuous mode.
This paper is organised as follows. The following section briefly
describes the development of a rigorous and general modelling
framework for crystallisation process. In Section 3, the idea of
designing and controlling continuous MSMPR crystallisers is
discussed based on the optimal solute concentration trajectory
in C-control. Section 4 considers the application of the proposed
modelling framework to a batch antisolvent crystallisation process
and compares the result to that obtained using conventional
modelling assumptions or Process Systems Enterprise (PSE)’s
gCRYSTAL package. The changeover and control from batch to
continuous operation using single-stage and cascaded two-stage
MSMPR crystallisers are also demonstrated and discussed. Finally,
concluding remarks are made in Section 5.
2. Rigorous modelling of a continuous MSMPR crystalliser
Crystallisation has a long history in the process industries for
separation and purification operations. Mathematical modelling of
continuous MSMPR crystallisers can be dated back to the 1950s or
even earlier [26]. A conventional assumption is that the dissolution
and crystallisation of solid crystals results in negligible volume
changes to the solution; or equivalently those volumes of solute
and solid crystals in the solution are assumed to be negligible. Such
assumptions have been widely applied for sparingly soluble
inorganic solutes, which form the “thin-suspension” solutions
[5]. For example, for a population balance over a macroscopic
region V with perfect mixing, defined as the solids-free volume,
m3, as shown below,
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where n is the population density based on solids-free volume,
#m3; G is the crystal growth rate, m s1; L is the characteristic
lengthof crystal,m; Lk is the inputandoutputflowrateof solids-free
liquid with a population density nk, m3 s1; Ss is the free surface
of the solids-free liquid, m2; Se is the total particle-fluid interface,
m2; v is the average velocity normal to the surface, m s1; Vs is
the change at the free surface of the solids-free volume of liquid
andVe is the volume occupied by the solids,m3. It is in Eq. (2) where
the conventional assumptions are applied, viz., only the solvent or
antisolvent additions are considered for Vs, while the Ve term is
completely neglected for the case of the “thin suspension” solution.
It is noted that recent studies of pharmaceutical crystallisations,
eitherbatchorcontinuous,usuallyemployedthepopulationbalance
and mass balance equations based on these assumptions. However,
this kind of assumptionsmay be a problem for highly soluble solute
systems in pharmaceutical and fine chemical crystallisation
processes and, in particular, when the product yield is high. For
example, the solubility of paracetamol in isopropanol and water
mixtures could be high around 200g per kg of solvents and with a
reported molar volume of 128.82 cm3mol1 or 1174kgm3 for the
mass density [27]. On the other hand, the density of solid
paracetamol crystal is reported as 1263kgm3. Therefore, neglect-
ingparacetamolsoluteandcrystalvolumes,or theirvolumechanges,
can lead to incorrect calculation of solute concentration, nucleation
rate, and some volumetric properties, such as the solution volume.
Furthermore, the solution volume, slurry density, and mean
residence time are more important variables for continuous
crystalliser design than for batch operations.
Hence, rigorous considerations of thermodynamic properties,
such as the partial molar volumes of solute and solvents, molar
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volume of crystal, are important and necessary for a continuous
MSMPR crystalliser designed for use in the pharmaceutical and
fine chemical industries. In this study, a general and rigorous
modelling framework is developed for a stirred tank crystalliser,
which can be used for cooling and antisolvent crystallisations in
either batch/semi-batch or continuous modes.
The proposed modelling framework is also derived from the
population balance of Eq. (1), while the population density, f (L), is
based on the total volume of the system slurry (Vslurry) instead, as
illustrated below. Thus the explicit calculation of Eq. (2) could be
avoided.
@f
@t
þ G@f
@L
¼ S
k
Qknk (3)
f ¼ nVslurry ¼ nðV liquid þ VsolidÞ (4)
where f is the population density based on total slurry volume, #;
Qk is the slurry volumetric flow rate of stream k to/from crystalliser,
m3 s1; Vliquid and Vsolid are the liquid and solid volume in
crystalliser, respectively, m3.
The standard method of moments is then applied to Eq. (3)
which leads to the moments of the crystal size distribution in the
total slurry volume. The proposed modelling framework is
demonstrated as follows, where mass balances for components,
such as solute, solvent, antisolvent, and crystal, are also included.
Incidentally, it is assumed that the nucleation occurs only in the
liquid solution as indicated in Eqs. (5) and (9)–(12).
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where Ni is the total moles of component i in the crystalliser, mol;
Fk is the slurry molar flow rate of stream k to/from crystalliser,
mol s1; xk,i is the mole fraction of component i in stream k; Kv is
the volume shape factor of crystal; vcry is the molar volume of
crystals, m3mol1; vi is the partial molar volume of component i in
liquid solution, m3mol1; G is the crystal growth rate, m s1;Mj is
the jth moment of crystal size distribution in the crystalliser, mj; B
is the nucleation rate, #m3 s1; r0 is the size of nuclei, m; mj,k is
the jth moment per volume of slurry stream k, mjm3. Note that
volumes of liquid and solid are rigorously calculated from (partial)
molar volumes in Eqs. (14) and (15).
3. From batch to continuous crystallisation using an MSMPR
Despite several advantages related to continuous processing,
such as, high throughput, more straightforward scale-up, elimina-
tion of intermediate storage, and consistent production, the
pharmaceutical industry has been slow to adopt the principle of
continuous operation due to the high investment cost for new
manufacturing equipment [28]. On the other hand, the strict
regulation in pharmaceutical approval systems, e.g. FDA inUS, EMA
in Europe, could create regulatory uncertainty about the approval
of the product when innovative and drastic changes are imposed
on the current manufacturing process [9,29]. Nevertheless,
changing the operation within the design-space of an approved
process is well accepted and a regulatory post-approval of the
process is not required [30], which has already opened up the
possibility for process optimisation [31]. Toward this end, based on
the existing stirred tank crystallisers, a conservative and practical
transition from batch to continuous crystallisation is proposed,
which constrains the changeover within the design-space of the
original batch crystallisation process.
The concentration control (C-control) strategy was originally
designed to control batch crystallisation processes by following a
predefined optimal solute concentration vs. temperature or
antisolvent mass fraction trajectory, which defines the design-
space of the batch process. The C-control strategy is schematically
shown in Fig.1 for a batch crystallisation process [20]. This optimal
trajectory is usually intended as a trade-off between nucleation
and crystal growth, i.e. to restrict the supersaturation level to
control nucleation rate, while maintaining a certain level of
supersaturation to boost crystal growth. Such an approach
generates a trajectory bounded between the metastable limit
and solubility curve on the phase diagram, as indicated by line AB
in Fig. 1. Fundamental cascaded PI control loops would usually
suffice to track this optimal trajectory, due to the requirement
for a monotonically decreasing solute concentration and relatively
slow crystallisation kinetics under conservative supersaturation
level; the robustness of the approach against uncertainties in
crystallisation kinetics has been clearly explained and also
demonstrated experimentally and in simulation [17–19].
The batch crystallisation operation requires repeated following
of the predefined trajectory AB, which demands a great deal of
control intervention to the system, such as regulating the cooling
rate, varying the addition flow rate of antisolvent, charging and
discharging the crystalliser. Without control, the batch operation
trajectory is difficult to follow and hence the system is liable to
suffer from inconsistent production with quality attributives
varying from batch to batch. Although C-control is robust, there
is an associated cost due to its conservativeness in the supersatu-
ration level. In fact, relatively long batch time may often be
required to compensate for the uncertainties in crystallisation
kinetics [17–19]. On the contrary, a continuous crystallisation
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process would maintain its operation at a steady-state operating
point (or a set of operating points for distributed systems),
demanding fewer regulating control efforts and assuring more
consistent production of crystals. The steady-state operating point
(s) of a continuous process would naturally be located on the
optimal trajectory shown in Fig. 1, so long as this trajectory makes
the best trade-off between nucleation and crystal growth. With an
aim of quick development and making minimum changes to the
whole manufacturing streamline, the changeover from batch to
continuous mode of a current crystallisation process would be
conservative by setting the steady-state operating point to be at
the end of this optimal trajectory, viz., point B in Fig. 1(a) for a
single-stageMSMPR crystallisation process; thus the same product
yield and similar quality attributives could be expected.
On the other hand, it is also obvious from Fig. 1(a) that one
possible way of starting up a continuous crystallisation process
from point A, to reach the MSMPR operation at point B, is to first
operate the stirred-tank crystalliser as a normal batch operation
following the optimal trajectory AB by C-control strategy and then
to shift to continuous MSMPR operation by streaming solution in
and out of the crystalliser while maintaining constant slurry
volume when the system reaches at point B, as shown by the dash
arrow line in Fig. 1(a). Thus, the production of off-spec material
during the initial transient start-up of a continuous process could
be minimised. Beside the PI control loop for C-control implemen-
tation during start-up, PI control loops could also be added under
the same idea of C-control to maintain the steady-state operation
at point B bymanipulating the flow rate of coolant to the jacket, or
feeding fresh solution and antisolvent to the crystalliser. The
cooling down of the feed solution A, or directlymixing it with large
amount of antisolvent, in the start-up of a continuous MSMPR
crystalliser to reach the operating point B, (known as the general
start-up procedure), could possibly generate relatively high
supersaturation and hence induce uncontrolled nucleation as
illustrated in Fig. 1(a) by the continuous arrow line. In contrast, the
proposed start-up operation for continuous MSMPR crystallisation
by C-control is able to ensure that the start-up procedures and
operating point(s) are well-controlled and well maintained within
the design-space of the original batch crystallisation process.
Note that it is very common for pharmaceutical industries to
employ parallel production lines for batch operation to increase
processing capacity. Hence, cascaded multi-stage continuous
MSMPR crystallisers would be an interesting alternative for
transferring current parallel batch operation to cascaded continu-
ous mode by connecting several stirred tank crystallisers in
sequence. Analogously, for multi-stage continuous process, the
operating point for the last stage could also be set at point B, and
identical start-up procedures and online control could be applied
as well, as shown in Fig. 1(b). Without any loss of generality, the
following section discusses the design of a cascaded two-stage
arrangement. The extension to cascaded arrangements with more
than two stages is straightforward.
The steady-state operating point of the first stage crystalliser is
located in between the starting point A and the end point B of the
optimal trajectory, viz., point C in Fig. 1(b). Likewise, the first stage
crystalliser could be started up to reach the operating point C by
following the optimal trajectory from A to C using the C-control
strategy and then maintained at its steady-state operating point at
C. Suppose the total batch time from A to B is tB, and the time
needed for the batch process going from A to C is tC, then the start-
up procedure of this two-stage crystallisation process could be
scheduled, such that the last stage crystalliser starts earlier as a
normal batch crystalliser from A to B, then followed by the start of
the first stage crystalliser at time tB–tC (also as a batch moving to
point C from A) so that they can reach their steady-state operating
points of B and C, respectively, at the same time, viz., at time tB.
Then the changeover from batch to continuous operation for the
cascaded arrangement can be completed seamlessly. This start-up
method is also within the design-space of the batch crystallisation
process and avoids the risk of introducing large nucleation rates
when compared to the general start-up procedure that initialises
the cascaded crystallisers in sequence, as shown in Fig.1(b); in that
case the two stages also reach their steady-state operations in
sequence.
Furthermore, for the design of a general n-stage cascaded
crystallisers as shown in Fig. 2, the optimal selection of the
operating points for the first (n1) stages could be considered, in
which the following objective function is minimised:
MIN
Ci;set ;Ti;set ;Mi;set ;g i
JssðPnÞ þS
n
j
EjWE
T
J (16)
[(Fig._1)TD$FIG]
Fig. 1. Schematic of the C-control strategy for batch crystallisation process and its
applications to start-up of continuous crystallisation process: (a) single-stage (b)
two-stage (continuous arrow line: general start-up; dash arrow line: C-control
start-up).
[(Fig._2)TD$FIG]
Fig. 2. Schematic of general n-stage cascaded crystallisers.
44 Q. Su et al. / Chemical Engineering and Processing 89 (2015) 41–53
subject to
i ¼ 1;2; . . . ;n 1 (17)
j ¼ 1;2; . . . ;n (18)
Ej ¼ Cj;ss  Cj;set; Tj;ss  Tj;set;Mj;ss Mj;set
 
(19)
f ðCi;set; Ti;set;Mi;set;Vi;batchÞ ¼ 0 (20)
g iVi;batch  Vmax (21)
Cj;set  Cj1;set (22)
where Jss is the objective function at steady state operation; Pn is
the product qualities at the exit of the nth stage crystalliser; Ej is
the control error for the jth stage crystalliser at steady state;W is a
diagonal weighting matrix; Cj,ss is the solute concentration of jth
stage crystalliser at steady state; Cj,set is the set point for
concentration of the jth stage crystalliser; similar definitions
apply to temperature (T) and antisolvent mass fraction (M); Vi,
batch is the corresponding volume when a normal batch
crystalliser follows the optimal trajectory and reaches the ith
stage operating point (Ci,set,Ti,set, Mi,set) under a nominal batch
operation f; g i is the scaling up factor for the ith stage crystalliser;
hence, g iVi,batch is the actual operating volume of ith stage
crystalliser at steady state; Vmax is the maximum allowable
operating volume for a stirred tank crystalliser. It is worth pointing
out that for a semi-batch antisolvent crystallisation, Vi,batch
[(Fig._3)TD$FIG]
Fig. 3. Comparison of slurry volume between case (1) negligible solute & solid volume (left) and case (2) rigorous modelling under ideal mixing (right). (Legend arranged in
descending order of volume, same as Fig. 8).
[(Fig._4)TD$FIG]
Fig. 4. Comparison of concentrations between case (1) negligible solute & solid volume and case (2) rigorous modelling under ideal mixing assumption.
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increases with a decrease of Cj,set in a nominal batch operation f
due to the continuous addition of antisolvent. For example, if Cj,set
is chosen close to the starting point A as in Fig. 1(b), then the
operating volume of jth crystalliser Vi,batch would be far smaller
than the maximum allowable operating volume Vmax. Thus an
additional scaling up factor g i is introduced to optimise the
respective operating volumes of the first (n1) crystallisers at
steady state. The constraint (22) is to confirm that the operating
points of concentration are in a descending order along the stages.
It is also noted that a large penalty weight ofWon the control error
in the objective function (16) would make sure all the steady-state
operating points are attainable for the cascaded multi-stage
crystallisers. Incidentally, once the operating points are chosen, the
distributions of fresh slurry or antisolvent are regulated by the PI
control loops in order to maintain their respective steady-state
operating points.
4. Results and discussion
4.1. Rigorous modelling and verification
To demonstrate the potential use of a rigorous modelling
approach in pharmaceutical crystallisation, the developedmodel is
applied, based on the MATLAB R2013b platform, for a semi-batch
[(Fig._5)TD$FIG]
Fig. 5. Comparison of concentrations between rigorous modelling in MATLAB and in gCRYSTAL.
[(Fig._6)TD$FIG]
Fig. 6. Comparison of moments of crystal size distribution between rigorous modelling in MATLAB and in gCRYSTAL.
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antisolvent crystallisation using paracetamol in acetone and water
(antisolvent) mixture in a stirred tank crystalliser [20]. The
crystalliser is first initialised with 0.30 L of a seeded solution (seed
mass = 0.4125 g, number-mean size 187.50mm) saturated at an
antisolvent mass fraction of 0.60. Continuous addition of
antisolvent is then introduced to increase the supersaturation
during a batch time of 2h. For more details of the experiment,
crystallisation kinetics and solubility, readers are referred to the
original reference in [20]. The resulting antisolvent addition flow
rate profile is determined by the C-control strategy to constantly
trade off the nucleation and crystal growth and is considered for
two cases where different assumptions are applied for the
calculation of volumes of the components in the crystalliser. Case
(1) assumes negligible (partial) molar volumes for solute and solid,
except in Eqs. (5) and (8) for the sake of the solute mass balance,
which should correspond to the results shown in [20]. In contrast,
case (2) considered the ideal mixing rule,, constant molar volumes
for all the components in the crystalliser.
Fig. 3 shows a comparison of the slurry volume and its
components in the crystalliser for each of the two cases. The left
plot shows case (1) in which the simulation assumes negligible
solute and solid volume in solution, whereas the right one shows
case (2) using the ideal mixing rule. It is observed in the right plot
that the solute volume occupies a significant portion in the liquid
and it decreases as the solute precipitates out as crystals. However,
under the assumption of negligible solute and solid volume, the
solvents volume is greater, which affects the solute solubility and
concentration as indicated in Fig. 4. Significant differences in the
absolute supersaturation are also observed, which have a great
impact on the simulation of primary nucleation and the resulting
amount of fine crystals. Therefore, it is interesting and necessary to
apply a rigorous modelling framework to crystallisation systems
that contain highly soluble solute in pharmaceutical and fine
chemical industries.
It should be pointed out here that the model compound of
paracetamol (acetaminophen) is still a small molecule with a
molecular weight of 151 gmol1 and thus constant (partial) molar
volumes are assumed here. Furthermore, due to the low yield, the
change of overall slurry volume due to the crystallisation effect is
not so obvious. However, for therapeutic proteins that have
complex molecular structure and varying partial molar volumes
due to the change of solution pH value or ion strength, their
[(Fig._7)TD$FIG]
Fig. 7. Comparison of slurry volumebetween general start-up (left) and proposed start-up (right) (the vertical line at 120min shows the changeover frombatch to continuous
crystallization for the proposed start-up, same as Figs. 8–10).
[(Fig._8)TD$FIG]
Fig. 8. Comparison of antisolvent and fresh slurry feeding between general start-up and proposed start-up.
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corresponding crystallisation effects could be much more
significant and important, as suggested in [16].
To further verify the developed rigorous modelling framework,
another simulation of the above antisolvent crystallisation process
was performed in gCRYSTAL v3.0 but with a different seed loading
(gCRYSTAL requires the seed crystal size distribution, while only
moments are provided by Woo et al. [20] and hence a new seed
loading with log-normal crystal size distribution (mean location =
180mm, standard deviation =2.0) was considered here while
others remain the same). In addition, the calculated initial
moments in gCRYSTAL were also input to the rigorous model
considering the ideal mixing rule and simulated in MATLAB
R2013b. The ideal mixing rule is implemented in gCRYSTAL and
thus nearly identical results should be obtained for the two
platforms, verifying the rigorous model development in the above
section. Comparisons between the two sets of results are shown in
Figs. 5 and 6. Excellent agreement in the predicted solute
concentrations were obtained, while the small mismatches in
the moments could be due to the different formulation and
solution of the partial differential equation (PDE) for the
population balance model. In gCRYSTAL, the population balance
PDE is discretised using central finite difference approximations
[(Fig._9)TD$FIG]
Fig. 9. Comparison of concentrations between general start-up and proposed start-up.
[(Fig._10)TD$FIG]
Fig. 10. Comparison of moments of crystal size distribution between general start-up and proposed start-up.
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into a set of ordinary differential equations (ODEs), which are
solved using themethod of backward differential formula (BDF). In
contrast, the rigorous model implemented here in MATLAB
converts the population balance PDE into a set of moment-based
ODEs, as shown in Eqs. (9)–(12), which are then solved numerically
using ODE45 (Runge–Kutta).
4.2. Continuous crystallisation using MSMPR
To demonstrate the proposed idea of converting batch
crystalliser into continuous one using MSMPR operation, the
aforementioned paracetamol crystallisation process in [20] is
further employed. The optimal concentration vs. antisolvent mass
fraction trajectory for C-control strategy therein is also adopted
here to facilitate the proposed process design of MSMPR
crystalliser. Note that this optimal trajectory is solely based on a
constant trade-off between the nucleation and crystal growth
kinetics,
K ¼ G
B
¼ kgDC
g
kbDC
b
 !
¼ 7 102 ms
1
m3s1
 
(23)
DC ¼ Kkb
kg
 1=ðgbÞ
(24)
whereK is the trade-off ratio.Hence itsoptimality isheldwhetheror
not the solute and solid crystal volumesare considered in thiswork.
Nevertheless, the following simulations are based on the rigorous
model under the ideal mixing rule within MATLAB R2013b.
For a single stirred tank crystalliser, as discussed in Section 3,
the proposed start-up and changeover from batch to continuous
operation can be taken as a normal batch operation followed by
maintenance of its steady-state operating point at the optimal
concentration trajectory by C-control, as can be seen in Figs. 7–10.
The proposed start-up procedure first initialises the stirred tank
crystalliser with 0.30 L seeded solution saturated at 60% water
mass fraction, followed by the C-control procedure to reach the
end point of the optimal concentration trajectory at time 120min,
and which finally stabilises its operation at this end point (see
horizontal line in Fig 9). Thereafter, two PI control loops are used to
control the antisolvent mass fraction and absolute supersaturation
by regulating antisolvent addition and fresh slurry feeding,
respectively (see the flow rates after the vertical line in Fig. 8).
Incidentally, the slurry level in the crystalliserwas kept constant by
regulating the outflow of product stream as shown in Fig. 7. This
start up method is contrasted with the general start-up procedure
which was initially filled with 0.44 L of the same starting solution
and directly pumps in/out using the steady-state flow rates of the
proposed start-up procedure so that they have the same mean
residence time under continuous operation and reach the same
final steady-state point (see Figs. 7–10).
Compared to the general start-up, the proposed scheme gives a
shortened time to steady state and avoids the initial large
supersaturation and primary nucleation rate (m0, zeroth moment),
as shown in Figs. 8 and 10. Furthermore, there is no product
outflow with low yield that needs to be recycled or reworked
during the proposed start-up, as a batch operation is adopted here
and thus there is no exiting flow in the early transient stages. More
importantly, the proposed operation could be regarded as being
within the design-space of the batch operation, which should have
been previously approved.
For a cascaded MSMPR design, by following Fig. 1(b) and the
optimal design of Eqs. (16)–(22), two-stage MSMPR crystallisers
(S1 and S2) in cascade are also designed in this work. An
objective function maximising the number-based mean crystal
size Ln is considered in the objective function of Eq. (16), which
finds the operating point in the optimal concentration trajectory
for the first stage crystalliser at 0.14 kg solute per kg solvents
and 0.67 for concentration and antisolvent mass fraction,
respectively; and a total operating volume of 0.35 L with a
scaling up factor g of 0.98 at steady-state. As previously
mentioned, the second stage crystalliser is maintained at its
steady-state operation at the end of the optimal concentration
trajectory. It is interesting to point out that the scaling up factor
is slightly lower than 1; this should be due to the penalty term
in the optimisation problem (16) to make sure the operating
points are attainable under continuous operation.
[(Fig._11)TD$FIG]
Fig. 11. Comparison of concentrations between general start-up and proposed start-up in the first stage crystalliser S1.
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The proposed start-up operations of the two-stage crystallisers
S1 and S2 can be seen in Figs. 11–13. While the crystalliser S2 is
startedasanormalbatchprocess for thefirst120min, thecrystalliser
S1 is initially filled with (0.980.30) L starting seeded solution
saturated at 0.60 antisolvent mass fraction and also held for
52.50min, it then follows the optimal concentration trajectory by
C-control to reach the set point, and finally settles down at this set
point for continuousoperation at the same timeas the crystalliser S2
at 120min (see the vertical line). Due to the low yield in crystalliser
S1 (seeTable 1), onlymarginal differences are observedbetween the
general start-up and proposed start-upprocedures in Figs.11 and 12
in terms of time to steady state and primary nucleation rate.
However, analogous to the case of a single MSMPR crystalliser, the
second stageMSMPR crystalliser also shows amuch faster approach
to the designed operating points and avoids a large amount of
primarynucleationduring start-upoperation (the results are similar
to Figs. 9 and 10, but are not shown here). The distribution of
antisolvent and slurry additions between the two-stage crystallisers
[(Fig._12)TD$FIG]
Fig. 12. Comparison of moments of crystal size distribution between general start-up and proposed start-up in the first stage crystalliser S1.
[(Fig._13)TD$FIG]
Fig. 13. Addition flow rates of antisolvent and fresh slurry for cascaded two-stage crystallisers.
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is shown inFig 13. Interestingly, it is noted that all the slurry solution
goes tothefirst stagecrystalliserat thesteady-stateoperation,which
is consistent with the results found by Frawley [32] who also
optimised a cascaded two-stage MSMPR crystalliser.
The overall steady-state performances are summarised and
compared for the above batch crystalliser, continuous single-stage
and cascaded two-stage MSMPR crystallisers in Table 1. There are
smaller number mean crystal size and slightly lower yield for the
continuous MSMPR operations; this is mainly due to the fact that
primary nucleation rates are higher at higher antisolvent mass
fractionwhere the continuousMSMPR operation points are located.
Although, there are also relatively higher productivities of solid
crystals, for shortenedmean residence times of the feeding streams.
4.3. Online control of MSMPR crystallisers
The C-control strategy has been well acknowledged for its
robustness against the uncertainties in crystallisation kinetics for
batch crystallisation control (see Woo et al. [20] for full details of
the C-control methodology). Hence it would be interesting to
confirm the robustness of C-control in the current continuous
MSMPR crystallisation process. Here we define “flow rate control”
Table 1
Comparison of different crystallization processes.
Processes t (min) Ln (mm) Yield (%) Productivity (g h1)
Batch 120.00 484 26.40 6.03a
Continuous 73.81 389 24.34 9.03
Cascade S1 44.88 310 7.61 4.72
Cascade S2 45.03 422 23.97 14.88
a Down time for batch operation is not considered.
[(Fig._14)TD$FIG]
Fig. 14. Online control performances by flow rate control and C-control in crystalliser S2 under growth rate uncertainty.
[(Fig._15)TD$FIG]
Fig. 15. Antisolvent flow rates to crystalliser S2 by flow rate control and C-control under growth rate uncertainty.
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in which the addition flow rates of antisolvent and fresh seeded
solution are controlled at their steady-state value, i.e. the same as
the general start-up procedure. In contrast, the C-control approach
maintains the antisolvent mass fraction and supersaturation
at their respective steady-state set points by regulating the
antisolvent addition and fresh slurry, respectively.
In Figs. 14 and 15, the crystal growth rate coefficient (kg) is
reduced by 20% from its nominal value and sluggish crystal growth
occurs from 600min onward. The performances of flow rate
control and C-control for the 2nd stage crystalliser S2 in the
cascaded two-stage MSMPR crystallisers are compared. By
maintaining the steady-state antisolvent and fresh slurry flow
rates (see Fig. 15); the flow rate control can hold the antisolvent
mass fraction, and thus the solubility, at its steady-state value.
However, the concentration and the supersaturation are disturbed
from their steady-state values when the uncertainty in crystal
growth rate occurs as shown in Fig. 14. On the contrary, the
C-control procedure brings back the supersaturation at its
steady-state set point while maintaining the antisolvent mass
fraction by reducing the antisolvent feed rate (see Fig. 15).
Interestingly, the fresh slurry feed rate is again kept constant at
zero, the same as under normal steady-state operation. Both the
antisolvent and fresh slurry feed rates were reduced in 1st stage
crystalliser analogously (results not shown here) to account for the
reduced crystal growth rate for paracetamol. Comparisons of the
number-based mean crystal size for both control strategies are
shown in Fig. 16, where the number mean crystal sizes are nearly
retained at their previous steady-state values by C-control.
Nevertheless, similar to the drawback of C-control in batch
operation, which extends the batch time to tackle the sluggish
crystal growth, the reduced addition flow rates by C-control for
continuous operation also lead to lower productivity at steady
state, i.e. from nominal 14.88 to 11.94 gh1, and longer mean
residence time from nominal 89.91 to 105.27min.
It is worth pointing out that, for moderate kinetic uncertainties
in crystal growth rate (>80% reduction in kg), the robustness of
C-control over the flow rate control is also demonstrated; although
a longer time to re-reach the steady state is required. However, for
moderate kinetic uncertainties in nucleation rate coefficient (kb),
since the continuous MSMPR crystalliser is already operated at the
optimal concentration vs. antisolvent mass fraction trajectory, that
is assumed to be the best trade off the nucleation and crystal
growth, they have no significant effects on the overall crystalliser
performance, such as solute concentration, volume-based mean
crystal size, etc. Hence the performance of flow rate control and
C-control are comparable [20]. Additionally, similar performances
were also observed when the C-control strategy was applied for
online control of a single-stage continuous MSMPR crystalliser.
5. Conclusions
The current study developed a general and rigorous mathe-
matical modelling framework for continuous MSMPR crystallisers.
The C-control strategy was further extended to facilitate the
convenient design of a start-up procedure and online control
technique for multi-stage continuous MSMPR crystallisers.
Thereby, the changeover from existing batch stirred-tank
operation to continuous MSMPR operation is well-within the
design-space of the original batch operation. It is observed that
despite the smaller mean crystal size, the proposed continuous
MSMPR operation achieves higher production capacity with
shorter mean residence time and comparable product yield as
in batch. The robustness of C-control strategy against uncertainties
in crystallisation kinetics was also demonstrated for the proposed
continuous MSMPR operation.
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